Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.
The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.
Haemonetics (HAE) disclosed an insider Form 4 for its EVP, Chief Commercial Officer. On 10/31/2025, 145 shares of common stock were withheld for taxes upon RSU vesting (code F) at $50.01 per share. Following this transaction, the reporting person directly beneficially owns 12,811 shares. This total includes unvested RSUs and 24 shares acquired under the company’s Employee Stock Purchase Plan on October 31, 2025.
Haemonetics insider transaction summary: Laurie A. Miller, SVP, Human Resources at Haemonetics Corp (HAE), reported a Form 4 showing a tax-withholding disposition tied to the vesting of restricted stock units. On 09/17/2025, 238 shares were disposed (transaction code F) at a price of $49.95 per share to satisfy tax obligations related to vested RSUs. After that transaction, Ms. Miller beneficially owned 28,925 shares, which the filing notes includes unvested RSUs previously reported. The Form 4 was signed by attorney-in-fact Thomas V. Powers on 09/24/2025.